Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca said the US Food and Drug Administration had granted the priority review for its metastatic breast cancer drug.
The review date for the drug was set for the cancer drug, was set for the second quarter of 2020.
'Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today,' said José Baselga, Executive Vice President, Oncology R&D.
'This priority review draws on the strength and the consistency of results seen in the Phase I and Phase II trials and is a critical step on the journey to deliver this potential new medicine to patients,' he added.
At 8:20am: (LON:AZN) AstraZeneca PLC share price was 0p at 6815p